TP53 and cancer: The Early Cancer Detection Test-Lung (EarlyCDT-Lung) test a prospective autoantibody panel for lung-cancer detection, yielded 9–16% six-month PPV in 1613 high-risk patients, depending on six-autoantibody (p53, New York Esophageal Squamous Cell Carcinoma 1 [NY-ESO-1], CAGE, GBU4-5, SOX2, Human Neuronal Protein D [HuD]) versus seven-autoantibody (p53, NY-ESO-1, CAGE, GBU4-5, SOX2, HuD, Melanoma-associated antigen 4 [MAGE A4]) model (94).